Evidence map›Paper›PMID 29075114›Full record

ArticleInternational journal of nanomedicine2017

A bone-resorption surface-targeting nanoparticle to deliver anti-miR214 for osteoporosis therapy.

Mingxiang Cai, Li Yang, Shufan Zhang, Jiafan Liu, Yao Sun, Xiaogang Wang

Expression of concernOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nanomedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It carries an expression of concern. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 58 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Targeting Agents in Biomaterial-Mediated Bone Regeneration.International journal of molecular sciences · 2023
    Review
  12. Article
  13. Curative Cell and Gene Therapy for Osteogenesis Imperfecta.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2022
    Review
  14. Review
  15. Review
  16. Review
  17. Poor bone matrix quality: What can be done about it?Current osteoporosis reports · 2021
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Mingxiang Cai *Engineering Research Center of Tooth Restoration and Regeneration, Department of Oral Implantology, School of Stomatology, Tongji University, Shanghai.
Li Yang *Department of Cell Biology, Institute of Biomedicine, College of Life Science and Technology, Jinan University, Guangzhou, China.
Shufan ZhangEngineering Research Center of Tooth Restoration and Regeneration, Department of Oral Implantology, School of Stomatology, Tongji University, Shanghai.
Jiafan LiuDepartment of Cell Biology, Institute of Biomedicine, College of Life Science and Technology, Jinan University, Guangzhou, China.
Yao SunEngineering Research Center of Tooth Restoration and Regeneration, Department of Oral Implantology, School of Stomatology, Tongji University, Shanghai.
Xiaogang WangDepartment of Cell Biology, Institute of Biomedicine, College of Life Science and Technology, Jinan University, Guangzhou, China.
Jinan University · CNTongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With increasing fracture risks due to fragility, osteoporosis is a global health problem threatening postmenopausal women. In these patients, osteoclasts play leading roles in bone loss and fracture. How to inhibit osteoclast activity is the key issue for osteoporosis treatment. In recent years, miRNA-based gene therapy through gene regulation has been considered a potential therapeutic method. However, in light of the side effects, the use of therapeutic miRNAs in osteoporosis treatment is still limited by the lack of tissue/cell-specific delivery systems. Here, we developed polyurethane (PU) nanomicelles modified by the acidic peptide Asp

Indexed as

AnimalsBone DensityBone Density Conservation AgentsBone ResorptionDrug Delivery SystemsFemaleGene Expression RegulationHumansMice, Inbred C57BLMicroRNAsNanoparticlesOsteoclastsOsteoporosisPolyurethanesBone Density Conservation AgentsMicroRNAsMirn214 microRNA, mousePolyurethanesbone resorptionmicroRNAnanoparticleosteoporosistargeting delivery

Identifiers

PMID29075114
PMCPMC5648312
OpenAlexW2762316552

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.